Literature DB >> 8251115

Role of DNA topoisomerase II in chromosome dynamics in mammalian cells.

T Andoh1, M Sato, T Narita, R Ishida.   

Abstract

ICRF-193, a bis-(2,6-dioxopiperazine) derivative and a non-cleavable-complex-forming-type topoisomerase II inhibitor, inhibited cell division but allowed cells to traverse the cell cycle, leading to the accumulation of polyploid cells with 8C complements or more of DNA. Analysis of the mechanism of how cell division is inhibited by ICRF-193 revealed that: (1) replication of DNA was inhibited only at terminal stages; (2) CDC2 kinase was activated and cells enter absence-of-chromosome-segregation ('ACS') M-phase, where chromosomes are not fully condensed and are not separated, but other mitotic events, such as nuclear-envelope breakdown and cytoskeletal reorganization forming the spindle apparatus, take place, i.e. chromosome dynamics could be uncoupled from the other mitotic events which are normally co-ordinated with the former in mitosis; (3) cells successfully exit from mitosis to the next G1-phase to continue the cell cycle; (4) progression through 'ACS' M-phase appears to be lethal to the cells. All of these observations could be accounted for by inactivation of topoisomerase II activity of the cells caused by the drug. ICRF-193 was thus shown to be a valuable agent in elucidation of the role of topoisomerase II in genetic processes in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251115

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  7 in total

1.  Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line.

Authors:  Adam J Carpenter; Andrew C G Porter
Journal:  Mol Biol Cell       Date:  2004-09-29       Impact factor: 4.138

2.  Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression.

Authors:  Jennifer Rhodes; Adam Amsterdam; Takaomi Sanda; Lisa A Moreau; Keith McKenna; Stefan Heinrichs; Neil J Ganem; Karen W Ho; Donna S Neuberg; Adam Johnston; Yebin Ahn; Jeffery L Kutok; Robert Hromas; Justin Wray; Charles Lee; Carly Murphy; Ina Radtke; James R Downing; Mark D Fleming; Laura E MacConaill; James F Amatruda; Alejandro Gutierrez; Ilene Galinsky; Richard M Stone; Eric A Ross; David S Pellman; John P Kanki; A Thomas Look
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

3.  Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle.

Authors:  P Muñoz; M Z Zdzienicka; J M Blanchard; J Piette
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

4.  Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events.

Authors:  R Ishida; M Sato; T Narita; K R Utsumi; T Nishimoto; T Morita; H Nagata; T Andoh
Journal:  J Cell Biol       Date:  1994-09       Impact factor: 10.539

Review 5.  Topoisomerase IIα in chromosome instability and personalized cancer therapy.

Authors:  T Chen; Y Sun; P Ji; S Kopetz; W Zhang
Journal:  Oncogene       Date:  2014-10-20       Impact factor: 9.867

Review 6.  A Topology-Centric View on Mitotic Chromosome Architecture.

Authors:  Ewa Piskadlo; Raquel A Oliveira
Journal:  Int J Mol Sci       Date:  2017-12-18       Impact factor: 5.923

7.  The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells.

Authors:  Christine J Farr; Melissa Antoniou-Kourounioti; Michael L Mimmack; Arsen Volkov; Andrew C G Porter
Journal:  Nucleic Acids Res       Date:  2014-01-29       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.